The pharmaceutical giant finalized a landmark $5.5 billion agreement on Monday to resolve a decade of litigation, effectively establishing the corporate market rate for causing a terminal illness with baby powder.
According to filings submitted to the Securities and Exchange Commission, the settlement covers approximately 76,000 claims consolidated in a New Jersey federal court, officially transitioning the mass distribution of asbestos-laced hygiene products from a catastrophic public health failure into a successfully amortized operating expense.
The agreement, which effectively calculates the destruction of a consumer's reproductive system at roughly the retail price of a fully loaded Ford F-150, was immediately praised by Wall Street analysts as a prudent measure to clear the company's balance sheet of lingering regulatory overhang.
By consolidating these claims into a single predictable payout, we have proven that our long-term strategy of litigating until the plaintiffs literally die works exactly as intended.
A spokesperson for the Department of Justice, which declined to pursue criminal charges after unearthing internal memos showing that executives spent decades actively strategizing around the known presence of asbestos in their talc supply, confirmed the administration's approval of the civil resolution in a brief Monday statement. Sources close to the Senate Health, Education, Labor, and Pensions Committee indicated lawmakers have no immediate plans to review the settlement, citing a packed legislative calendar and a desire to look forward.
At press time, corporate leadership confirmed the $5.5 billion penalty will be comfortably absorbed through standard tax deductions and the continued, robust global sales of alternative consumer lotions currently being rubbed into the skin of millions of infants.